British Hospital

About: British Hospital is a healthcare organization based out in Montevideo, Uruguay. It is known for research contribution in the topics: Population & Lung cancer. The organization has 445 authors who have published 358 publications receiving 7878 citations. The organization is also known as: British Hospital.

Motor and cognitive performances in pre-lingual cochlear implant adolescents, related with vestibular function and auditory input.

Abstract: Background Information about the role of auditory input and motor control is limited. Objectives Assessment the relationship between auditory and vestibular information with specific motor and cognitive functions. Methods Posturography in 17 Pre-lingual Cochlear Implant Adolescents, (PCIA) age 14.06 ± 3.05 in four sensory conditions was analyzed: (A) eyes open, cochlear implant (CI) on, (B) eyes open, CI off, (C) eyes closed standing on a foam over a platform (ECFP) with CI on, and (D) ECFP, CI off. Gait velocity (GV) was registered by inertial sensors using a 10-meter test. Vestibulo-ocular reflex (VOR) was evaluated with the video head impulse test (VHIT) and visual spatial skill (VS) assessed with the WISC-V test. Results SV had no significant difference between conditions A and B (p = .2461). Comparing C and D, SV values decreased when CI was turned on (p = .0036). A significant linear relationship between VOR and GV (p = .0064) generating the VOR gain loss lower gait. Relationship between VOR and VS scores was no significant (p = .685). Conclusions and significance Auditory information is a relevant cue when somatosensory and visual inputs are modified and range of vestibular function influence in a dynamic motor activity as gait, facts which must be considered in the neurodevelopment control.

Ligament Reconstruction in Congenital Absence of the Anterior Cruciate Ligament: A Report of Two Cases.

Abstract: Congenital absence of the anterior cruciate ligament (ACL) is an extremely rare condition (0.017 per 1000 live births) [12]. It has been reported as an isolated entity [1, 14] or associated with other abnormalities such as congenital femoral deficiency, fibular hemimelia, scoliosis, hip dysplasia, and dysplasia of the tibial intercondylar eminence [4, 9, 10, 14]. It was first reported by Giorgi [8] in 1956 in a radiographic study, and since then, several case reports have been published [4, 11]. Most reports describe patients with no complaints of instability (despite having positive objective instability tests) but pain due to osteoarthritis of the medial femorotibial joint [12]. Individuals with this condition may not have symptomatic instability if they are able to use muscle forces to provide knee stability. The cases reported with symptomatic instability are likely due to an event that may alter the knee homeostasis making the ACL deficiency manifest [15]. Given the rarity of the condition, there is no consensus regarding the optimal therapeutic approach, although most studies conclude that non-surgical options are the appropriate management despite early degenerative joint disease. Anterior cruciate ligament reconstruction is indicated when symptoms of instability appear [6]. This is a report on two cases of congenital absence of the ACL, one with a femoral length discrepancy and another with a lateral femoral condyle hypoplasia and posterior cruciate ligament (PCL) dysplasia.

Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status.

Abstract: Triple negative breast cancer (TNBC) is a deadly disease with limited treatment options. Selinexor is a selective inhibitor of nuclear export that binds covalently to exportin 1 thereby reactivating tumor suppressor proteins and downregulating expression of oncogenes and DNA damage repair (DDR) proteins. Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of patients with breast cancer harboring BRCA mutations. We examined the effects of co-treatment with selinexor and olaparib in TNBC cell lines. BRCA1 wildtype (BRCA1-wt) and BRCA1 mutant (BRCA1-mut) TNBC cell lines were treated with selinexor and/or olaparib and effects on cell viability and cell cycle were evaluated. The effects of treatment were also evaluated in mouse xenograft models generated with BRCA1-wt and BRCA1-mut TNBC cell lines. Treatment with selinexor inhibited cell proliferation and survival of all TNBC cell lines tested in vitro. This effect was enhanced following treatment of the cells with the combination of selinexor and olaparib, which showed synergistic effects on tumor growth inhibition in MDA-MB-468-derived (BRCA1-wt) and MDA-MB-436-derived (BRCA1-mut) xenografts. As co-treatment with selinexor and olaparib exhibits anti-tumor activity regardless of BRCA1 mutation status, the clinical implications of the combination warrant further investigation.